

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G/A

BIOMARIN PHARMACEUTICAL INC  
Form SC 13G/A  
June 11, 2007

SCHEDULE 13G

Amendment No. 3  
BioMarin Pharmaceutical Incorporated  
Common Stock  
Cusip #09061G101

Cusip #09061G101  
Item 1: Reporting Person - FMR Corp.  
Item 4: Delaware  
Item 5: 1,140  
Item 6: 0  
Item 7: 5,777,366  
Item 8: 0  
Item 9: 5,777,366  
Item 11: 6.021%  
Item 12: HC

Cusip #09061G101  
Item 1: Reporting Person - Edward C. Johnson 3d  
Item 4: United States of America  
Item 5: 0  
Item 6: 0  
Item 7: 5,777,366  
Item 8: 0  
Item 9: 5,777,366  
Item 11: 6.021%  
Item 12: IN

SCHEDULE 13G - TO BE INCLUDED IN  
STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Item 1(a). Name of Issuer:  
BioMarin Pharmaceutical Incorporated

Item 1(b). Name of Issuer's Principal Executive Offices:  
105 Digital Drive  
Novato, CA 94949

Item 2(a). Name of Person Filing:  
FMR Corp.

Item 2(b). Address or Principal Business Office or, if None,  
Residence:

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G/A

82 Devonshire Street, Boston,  
Massachusetts 02109

Item 2(c). Citizenship:

Not applicable

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

09061G101

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, FMR Corp., is a parent holding company in accordance with Section 240.13d-1(b)(ii)(G). (Note: See Item 7).

Item 4. Ownership

(a) Amount Beneficially Owned: 5,777,366

(b) Percent of Class: 6.021%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote: 1,140

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of: 5,777,366

(iv) shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of BioMarin Pharmaceutical Incorporated. The interest of one person, Fidelity Growth Company Fund, an investment company registered under the Investment Company Act of 1940, in the Common Stock of BioMarin Pharmaceutical Incorporated, amounted to 5,610,793 shares or 5.847% of the total outstanding Common Stock at May 31, 2007.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G/A

Holding Company.

See attached Exhibit A.

Item 8. Identification and Classification of Members of the Group.

Not applicable. See attached Exhibit A.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 11, 2007  
Date

/s/Eric D. Roiter  
Signature

Eric D. Roiter  
Duly authorized under Power of Attorney  
dated December 30, 1997 by and on behalf of FMR Corp. and  
its direct and indirect subsidiaries

SCHEDULE 13G - TO BE INCLUDED IN  
STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity Management & Research Company ("Fidelity"), 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 5,777,366 shares or 6.021% of the Common Stock outstanding of BioMarin Pharmaceutical Incorporated ("the Company") as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940. The number of shares of Common Stock of BioMarin Pharmaceutical Incorporated owned by the investment companies at May 31, 2007 included 151,433 shares of Common Stock resulting from the assumed conversion of

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G/A

\$2,510,000 principal amount of BIOMARIN PHAR CV 2.5  
3/13 144A (60.3318 shares of Common Stock for each \$1,000  
principal amount of debenture).

The ownership of one investment company, Fidelity  
Growth Company Fund, amounted to 5,610,793 shares or  
5.847% of the Common Stock outstanding. Fidelity Growth  
Company Fund has its principal business office at 82  
Devonshire Street, Boston, Massachusetts 02109.

Edward C. Johnson 3d and FMR Corp., through its  
control of Fidelity, and the funds each has sole power to  
dispose of the 5,777,366 shares owned by the Funds.

Members of the family of Edward C. Johnson 3d,  
Chairman of FMR Corp., are the predominant owners, directly  
or through trusts, of Series B shares of common stock of FMR  
Corp., representing 49% of the voting power of FMR Corp.  
The Johnson family group and all other Series B shareholders  
have entered into a shareholders' voting agreement under  
which all Series B shares will be voted in accordance with the  
majority vote of Series B shares. Accordingly, through their  
ownership of voting common stock and the execution of the  
shareholders' voting agreement, members of the Johnson  
family may be deemed, under the Investment Company Act of  
1940, to form a controlling group with respect to FMR Corp.

Neither FMR Corp. nor Edward C. Johnson 3d,  
Chairman of FMR Corp., has the sole power to vote or direct  
the voting of the shares owned directly by the Fidelity Funds,  
which power resides with the Funds' Boards of Trustees.  
Fidelity carries out the voting of the shares under written  
guidelines established by the Funds' Boards of Trustees.

SCHEDULE 13G - TO BE INCLUDED IN  
STATEMENTS

FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)  
RULE 13d-1(f) (1) AGREEMENT

The undersigned persons, on June 11, 2007, agree and  
consent to the joint filing on their behalf of this Schedule 13G  
in connection with their beneficial ownership of the Common  
Stock of BioMarin Pharmaceutical Incorporated at May 31,  
2007.

FMR Corp.

By /s/ Eric D. Roiter  
Eric D. Roiter  
Duly authorized under Power of Attorney dated  
December 30, 1997, by and on behalf of FMR Corp. and its  
direct and indirect subsidiaries

Edward C. Johnson 3d

By /s/ Eric D. Roiter  
Eric D. Roiter  
Duly authorized under Power of Attorney dated  
December 30, 1997, by and on behalf of Edward C. Johnson  
3d

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G/A

Fidelity Management & Research Company

By /s/ Eric D. Roiter  
Eric D. Roiter  
Senior V.P. and General Counsel

Fidelity Growth Company Fund

By /s/ Eric D. Roiter  
Eric D. Roiter  
Secretary